$EBS
Emergent BioSolutions Inc. Stock $ebs

$ebs Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000136764422000070 Filed on April 29, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$307.5M	$343.0M
YoY Change	-10.35%	78.18%
Cost Of Revenue	$155.9M	$99.30M
YoY Change	57.0%	29.13%
Gross Profit	$142.0M	$222.4M
YoY Change	-36.15%	92.39%
Gross Profit Margin	46.18%	64.84%
Selling, General & Admin	$84.80M	$80.90M
YoY Change	4.82%	16.07%
% of Gross Profit	59.72%	36.38%
Research & Development	$46.40M	$52.50M
YoY Change	-11.62%	22.95%
% of Gross Profit	32.68%	23.61%
Depreciation & Amortization	$30.90M	$28.70M
YoY Change	7.67%	1.77%
% of Gross Profit	21.76%	12.9%
Operating Expenses	$131.2M	$133.4M
YoY Change	-1.65%	18.68%
Operating Profit	$6.400M	$95.40M
YoY Change	-93.29%	-922.41%
Interest Expense	$8.200M	$8.500M
YoY Change	-3.53%	-1.16%
% of Operating Profit	128.13%	8.91%
Other Income/Expense, Net	-$10.20M	-$10.20M
YoY Change	0.0%	5.15%
Pretax Income	-$3.800M	$85.20M
YoY Change	-104.46%	-500.0%
Income Tax	-$100.0K	$15.50M
% Of Pretax Income		18.19%
Net Earnings	-$3.700M	$69.70M
YoY Change	-105.31%	-657.6%
Net Earnings / Revenue	-1.2%	20.32%
Basic Earnings Per Share	-$0.07	$1.31
Diluted Earnings Per Share	-$0.07	$1.28
COMMON SHARES
Basic Shares Outstanding	50.70M shares	53.30M shares
Diluted Shares Outstanding	50.70M shares	54.50M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$435.8M	$547.8M
YoY Change	-20.45%	201.82%
Cash & Equivalents	$435.8M	$547.8M
Short-Term Investments
Other Short-Term Assets	$82.00M	$1.100M
YoY Change	7354.55%	-95.47%
Inventory	$400.7M	$406.5M
Prepaid Expenses
Receivables	$181.8M	$184.4M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.100B	$1.181B
YoY Change	-6.84%	88.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$807.5M	$692.9M
YoY Change	16.54%	26.17%
Goodwill	$224.9M	$266.5M
YoY Change	-15.61%	0.04%
Intangibles	$590.6M	$648.2M
YoY Change	-8.89%	-8.46%
Long-Term Investments
YoY Change
Other Assets	$57.10M	$111.4M
YoY Change	-48.74%	36.19%
Total Long-Term Assets	$1.680B	$1.719B
YoY Change	-2.26%	4.05%
TOTAL ASSETS
Total Short-Term Assets	$1.100B	$1.181B
Total Long-Term Assets	$1.680B	$1.719B
Total Assets	$2.780B	$2.900B
YoY Change	-4.13%	27.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$107.3M	$142.2M
YoY Change	-24.54%	68.88%
Accrued Expenses	$29.30M	$25.00M
YoY Change	17.2%	-39.76%
Deferred Revenue	$10.00M	$60.30M
YoY Change	-83.42%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$31.60M	$26.00M
YoY Change	21.54%	-1.14%
Total Short-Term Liabilities	$249.2M	$370.2M
YoY Change	-32.69%	78.75%
LONG-TERM LIABILITIES
Long-Term Debt	$801.5M	$833.1M
YoY Change	-3.79%	9.2%
Other Long-Term Liabilities	$49.30M	$62.90M
YoY Change	-21.62%	6.79%
Total Long-Term Liabilities	$850.8M	$896.0M
YoY Change	-5.04%	9.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$249.2M	$370.2M
Total Long-Term Liabilities	$850.8M	$896.0M
Total Liabilities	$1.205B	$1.377B
YoY Change	-12.5%	14.4%
SHAREHOLDERS EQUITY
Retained Earnings	$954.1M	$796.6M
YoY Change	19.77%	94.62%
Common Stock	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$204.4M	$39.60M
YoY Change	416.16%	0.0%
Treasury Stock Shares	4.900M shares	1.200M shares
Shareholders Equity	$1.575B	$1.523B
YoY Change
Total Liabilities & Shareholders Equity	$2.780B	$2.900B
YoY Change	-4.13%	27.27%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$3.700M	$69.70M
YoY Change	-105.31%	-657.6%
Depreciation, Depletion And Amortization	$30.90M	$28.70M
YoY Change	7.67%	1.77%
Cash From Operating Activities	-$37.30M	$5.100M
YoY Change	-831.37%	-91.18%
INVESTING ACTIVITIES
Capital Expenditures	$32.20M	$56.10M
YoY Change	-42.6%	131.82%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$32.20M	-$56.10M
YoY Change	-42.6%	131.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$57.50M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$70.50M	-$22.20M
YoY Change	217.57%	11.0%
NET CHANGE
Cash From Operating Activities	-$37.30M	$5.100M
Cash From Investing Activities	-$32.20M	-$56.10M
Cash From Financing Activities	-$70.50M	-$22.20M
Net Change In Cash	-$140.3M	-$73.50M
YoY Change	90.88%	-636.5%
FREE CASH FLOW
Cash From Operating Activities	-$37.30M	$5.100M
Capital Expenditures	$32.20M	$56.10M
Free Cash Flow	-$69.50M	-$51.00M
YoY Change	36.27%	-251.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001367644
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q1	us-gaap	Assets Assets	2780400000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Adjustment Period DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod	P12M
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-33137
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	EMERGENT BIOSOLUTIONS INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	14-1902018
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Professional Drive Suite 400
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
CY2022Q1	dei	City Area Code CityAreaCode	240
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	631-3200
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	EBS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50243624	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	435800000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	181800000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	400700000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	81800000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70300000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1100300000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1272100000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	807500000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	590600000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	604600000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	224900000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	224900000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57100000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57300000	USD
CY2021Q4	us-gaap	Assets Assets	2959000000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	107300000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	128900000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29300000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51700000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	56400000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	88700000	USD
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	31600000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	31600000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24600000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	72900000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	249200000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	373800000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4400000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4500000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	801500000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	94800000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	94900000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5900000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4700000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	49300000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	52700000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	1205100000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	1340000000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55300000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55100000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50400000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51300000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	4900000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3800000	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	204400000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	152200000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	834800000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	829400000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9300000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16100000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	954100000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	957800000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1575300000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2780400000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2959000000	USD
CY2022Q1	us-gaap	Revenues Revenues	307500000	USD
CY2021Q1	us-gaap	Revenues Revenues	343000000.0	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46400000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52500000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	84800000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80900000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14000000.0	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14900000	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	301100000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	247600000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	6400000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	95400000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	8200000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	8500000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000000.0	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1700000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10200000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10200000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3800000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	85200000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15500000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	69700000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.28
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50700000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53300000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50700000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54500000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	69700000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	500000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2200000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	900000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	6300000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	3100000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6800000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3100000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	70600000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	69700000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9900000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10500000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30900000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28700000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	500000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1100000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1000000.0	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1000000.0	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1900000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1700000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-600000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3500000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-93700000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42100000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50100000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	99900000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16600000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10000000.0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14700000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	20100000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-56500000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-40000000.0	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-32200000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-29400000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2000000.0	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9400000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37300000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5100000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32200000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56100000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32200000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56100000	USD
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	57500000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2022Q1	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	8500000	USD
CY2021Q1	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	5600000	USD
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2021Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10600000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	500000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6900000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000000.0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	12200000	USD
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2021Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-70500000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-22200000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-300000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-300000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-140300000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-73500000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	436000000.0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	548000000.0	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	11700000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	12400000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4800000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1500000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13300000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32500000	USD
CY2022Q1	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	1300000	USD
CY2021Q1	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	435800000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	436000000.0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5400000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	52200000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6800000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1575300000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1447000000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5200000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	69700000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	900000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1522800000	USD
CY2022Q1	ebs	Number Of Categories Of Public Health Threats NumberOfCategoriesOfPublicHealthThreats	5	category
CY2022Q1	ebs	Number Of Revenue Generating Products NumberOfRevenueGeneratingProducts	11	product
CY2022Q1	ebs	Number Of Product Candidates NumberOfProductCandidates	1	productCandidate
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	244100000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	217500000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	106000000.0	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	95800000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	50600000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	37500000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	400700000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1137300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1119200000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	329800000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	319100000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	807500000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1400000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1300000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	1700000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	1700000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26900000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28300000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5800000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5800000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22600000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24200000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28400000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30000000.0	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	832100000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	241500000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	590600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	832100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	227500000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	604600000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14000000.0	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14900000	USD
CY2022Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P11Y8M12D
CY2021Q4	us-gaap	Goodwill Goodwill	224900000	USD
CY2022Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	0	USD
CY2022Q1	us-gaap	Goodwill Goodwill	224900000	USD
CY2022Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	41700000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	41700000	USD
CY2022Q1	us-gaap	Derivative Assets DerivativeAssets	2500000	USD
CY2021Q4	us-gaap	Derivative Assets DerivativeAssets	0	USD
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	260100000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	352400000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7600000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	37200000	USD
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	6100000	USD
CY2022Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7600000	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	43300000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	37200000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	500000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	30100000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	7600000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3200000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	32700000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	841100000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	849600000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	31600000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31600000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8000000.0	USD
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8500000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	801500000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	2000000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1600000	USD
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Rolling Period DebtInstrumentCovenantNetLeverageRatioRollingPeriod	P12M
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Revenues Revenues	307500000	USD
CY2021Q1	us-gaap	Revenues Revenues	343000000.0	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1100000000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1100000000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2022Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	42200000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	21500000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16400000	USD
CY2022Q1	ebs	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	6400000	USD
CY2022Q1	ebs	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	6900000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15900000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11700000	USD
CY2022Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	115200000	USD
CY2021Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	224900000	USD
CY2022Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	66600000	USD
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	49800000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	181800000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	700000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3200000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.27
CY2022Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	400000	USD
CY2021Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-6600000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	69700000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50700000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53300000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1200000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50700000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54500000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.28
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1600000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9900000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10500000	USD
CY2022Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	5400000	USD
CY2022Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1400000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6800000	USD
CY2021Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-500000	USD
CY2021Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1400000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	900000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	9300000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	2500000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6800000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	200000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-700000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	900000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Revenues Revenues	307500000	USD
CY2021Q1	us-gaap	Revenues Revenues	343000000.0	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	142000000.0	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	222400000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	500000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1100000	USD
CY2022Q1	ebs	Adjusted Gross Margin AdjustedGrossMargin	142500000	USD
CY2021Q1	ebs	Adjusted Gross Margin AdjustedGrossMargin	223500000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	16600000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	13600000	USD

Files In Submission

Name	View Source	Status
0001367644-22-000070-index-headers.html	Edgar Link	pending
0001367644-22-000070-index.html	Edgar Link	pending
0001367644-22-000070.txt	Edgar Link	pending
0001367644-22-000070-xbrl.zip	Edgar Link	pending
a311-kramercert111.htm	Edgar Link	pending
a312-lindhalcert111.htm	Edgar Link	pending
a321-kramercert111.htm	Edgar Link	pending
a322-lindhalcert111.htm	Edgar Link	pending
biothraxcontractmod27edg.htm	Edgar Link	pending
biothraxcontractmod27edg001.jpg	Edgar Link	pending
ebs-20220331.htm	Edgar Link	pending
ebs-20220331.xsd	Edgar Link	pending
ebs-20220331_cal.xml	Edgar Link	unprocessable
ebs-20220331_def.xml	Edgar Link	unprocessable
ebs-20220331_g1.jpg	Edgar Link	pending
ebs-20220331_g2.jpg	Edgar Link	pending
ebs-20220331_g3.jpg	Edgar Link	pending
ebs-20220331_g4.jpg	Edgar Link	pending
ebs-20220331_g5.jpg	Edgar Link	pending
ebs-20220331_g6.jpg	Edgar Link	pending
ebs-20220331_g7.jpg	Edgar Link	pending
ebs-20220331_g8.jpg	Edgar Link	pending
ebs-20220331_g9.jpg	Edgar Link	pending
ebs-20220331_htm.xml	Edgar Link	completed
ebs-20220331_lab.xml	Edgar Link	unprocessable
ebs-20220331_pre.xml	Edgar Link	unprocessable
fehconsulting.htm	Edgar Link	pending
fehconsulting001.jpg	Edgar Link	pending
fehconsulting002.jpg	Edgar Link	pending
fehconsulting003.jpg	Edgar Link	pending
fehconsulting004.jpg	Edgar Link	pending
fehconsulting005.jpg	Edgar Link	pending
fehconsulting006.jpg	Edgar Link	pending
fehconsulting007.jpg	Edgar Link	pending
fehconsulting008.jpg	Edgar Link	pending
fehconsulting009.jpg	Edgar Link	pending
fehconsulting010.jpg	Edgar Link	pending
fehconsulting011.jpg	Edgar Link	pending
fehconsulting012.jpg	Edgar Link	pending
fehconsulting013.jpg	Edgar Link	pending
fehconsulting014.jpg	Edgar Link	pending
fehconsulting015.jpg	Edgar Link	pending
fehconsulting016.jpg	Edgar Link	pending
fehconsulting017.jpg	Edgar Link	pending
fehconsulting018.jpg	Edgar Link	pending
fehconsulting019.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EBS
Emergent BioSolutions Inc. Stock $ebs

2022 Q1 Form 10-Q Financial Statement

#000136764422000070 Filed on April 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS Emergent BioSolutions Inc. Stock $ebs

2022 Q1 Form 10-Q Financial Statement

#000136764422000070 Filed on April 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS
Emergent BioSolutions Inc. Stock $ebs